Eric L. Saunders
Associate, Intellectual Property
Eric L. Saunders is an associate in the Intellectual Property Department. Eric’s practice includes experience with patent litigation, at both the trial court and appellate levels, as well as client counseling on intellectual property issues that arise in transactions, including licensing, research and development, and mergers and acquisitions. He is an active member of Willkie’s trademark practice group, with experience advising clients in trademark litigation and trademark prosecution before the United States Patent and Trademark Office and abroad. Eric has litigation experience across an array of technologies, with a particular focus on pharmaceuticals, medical devices, and biotechnology.
Experience
New York State Bar Association “Empire State Counsel 2019” for commitment to serving pro bono clients.
Eric is a member of the New York Intellectual Property Law Association.
- The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, February 2021
- The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, November 2020
- The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, July 2020
- Willkie Obtains Significant Victory for Hospira in Pharmaceutical Patent Litigation, April 6, 2020
- The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, April 2020
- The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, January 2020
- The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, October 2019
- The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, July 2019
- The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, April 2019
- The Bio-Quarterly: Willkie’s Biologics and Biosimilars Newsletter, October 2018
- Roche Diabetes Care v. Insulet Corporation (insulin pump) – Representing Insulet in a patent infringement litigation brought by Roche Diabetes Care regarding the OmniPod insulin delivery system.
- Amgen v. Hospira (erythropoietin) – Represented Hospira in appeal of one of the first litigations under the BPCIA regarding Epogen.
- Belcher v. Hospira (epinephrine) – Successfully defended Hospira in ANDA litigation in which patent-in-suit was found invalid by the trial court.
- Par v. Hospira (epinephrine) – Represented Hospira in appeal of ANDA litigation at the Federal Circuit.
- Array v. Takeda – Represented Array in an IPR proceeding on Takeda’s compound patent which ultimately resulted in a favorable decision.
Credentials
Education
George Washington University Law School, J.D., 2017 University of Central Arkansas, M.A., 2014 Hendrix College, B.A., 2003